IP Library › Granted Patent US 12,589,162
Granted Patent B2
US 12,589,162 · App. 18/020,221 · Granted Mar 31, 2026

Trans-cyclooctene prodrug of monomethyl auristatin E

Inventors: Jose Manuel Mejia Oneto (San Francisco, CA); Nathan A. Yee (San Francisco, CA); Jesse M. McFarland (San Francisco, CA)
Assignee: Tambo, Inc.
A61K47/68A61K47/06A61K47/542A61K47/642A61P35/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,589,162
App. No.
18/020,221
Granted
Mar 31, 2026
Kind
B2
Abstract

6-(Carbonyloxy)-1-methylcyclooct-4-ene-1-carbonyl)-aspartic acid conjugate of monomethyl auristatin E may be used for bioorthogonal delivery to a targeted location in a subject in the treatment of cancer and tumor growths.

Claims (5)

1 . A compound:

or a pharmaceutically acceptable salt thereof.

2 . A pharmaceutical composition comprising the compound of claim 1 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

3 . A compound:

4 . A pharmaceutical composition comprising the compound of claim 3 and a pharmaceutically acceptable carrier.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 7, 2023
From: MEJIA ONETO, JOSE MANUEL; YEE, NATHAN A.; SRINIVASAN, SANGEETHA; ZAKHARIAN, MICHAEL; MCFARLAND, JESSE M.
To: TAMBO, INC.
Reel/Frame 062619/0366 →
Continuity (2)
Provisional Application 63062814 · Aug 7, 2020
Related Publication 20230256109A1 · Aug 17, 2023
References Cited (256)
US 4689338A · Gerster · 1987 [cited by applicant]
US 5770229A · Tanihara et al. · 1998 [cited by applicant]
US 8552183B2 · Wiessler et al. · 2013 [cited by applicant]
US 9421274B2 · Robillard et al. · 2016 [cited by applicant]
US 9427482B2 · Rossin et al. · 2016 [cited by applicant]
US 9463256B2 · Lub et al. · 2016 [cited by applicant]
US 10046002B2 · Zebala et al. · 2018 [cited by applicant]
US 10130711B2 · Mejia Oneto et al. · 2018 [cited by applicant]
US 10130723B2 · Mejia Oneto et al. · 2018 [cited by applicant]
US 10342882B2 · Mejia Oneto et al. · 2019 [cited by applicant]
US 10487149B2 · Geall et al. · 2019 [cited by applicant]
US 10806807B2 · Mejia Oneto et al. · 2020 [cited by applicant]
US 10828373B2 · Mejia Oneto et al. · 2020 [cited by applicant]
US 11253600B2 · Mejia Oneto et al. · 2022 [cited by applicant]
US 20030191291A1 · Kochendoerfer et al. · 2003 [cited by applicant]
US 20050014197A1 · Agnew et al. · 2005 [cited by applicant]
US 20060153893A1 · Matsuno et al. · 2006 [cited by applicant]
US 20070048302A1 · Theze et al. · 2007 [cited by applicant]
US 20080014222A1 · Simmons et al. · 2008 [cited by applicant]
US 20090023916A1 · Fox et al. · 2009 [cited by applicant]
US 20090304587A1 · Rubinstein et al. · 2009 [cited by applicant]
US 20100016545A1 · Wiessler et al. · 2010 [cited by applicant]
US 20100028435A1 · Gavard Molliard · 2010 [cited by applicant]
US 20110223257A1 · Zhao et al. · 2011 [cited by applicant]
US 20110268654A1 · Hilderbrand et al. · 2011 [cited by applicant]
US 20110293565A1 · Kandimalla et al. · 2011 [cited by applicant]
US 20110311518A1 · Kandimalla et al. · 2011 [cited by applicant]
US 20120034161A1 · Robillard et al. · 2012 [cited by applicant]
US 20120076727A1 · McBride et al. · 2012 [cited by applicant]
US 20130281644A1 · Kiessling et al. · 2013 [cited by applicant]
US 20130302246A1 · Hilderbrand et al. · 2013 [cited by applicant]
US 20140093450A1 · Robillard et al. · 2014 [cited by applicant]
US 20140199331A1 · Robillard et al. · 2014 [cited by applicant]
US 20140205653A1 · Dubensky, Jr. et al. · 2014 [cited by applicant]
US 20140303123A1 · Baker, Jr. et al. · 2014 [cited by applicant]
US 20150037359A1 · Schellenberger et al. · 2015 [cited by applicant]
US 20150218274A1 · Sabatos-peyton et al. · 2015 [cited by applicant]
US 20150259420A1 · Triebel et al. · 2015 [cited by applicant]
US 20160114046A1 · Brudno et al. · 2016 [cited by applicant]
US 20160120987A1 · Mejia Oneto et al. · 2016 [cited by applicant]
US 20160287623A1 · Gajewski et al. · 2016 [cited by applicant]
US 20170044206A1 · Altman et al. · 2017 [cited by applicant]
US 20170087258A1 · Oneto et al. · 2017 [cited by applicant]
US 20170095580A1 · Mejia Oneto et al. · 2017 [cited by applicant]
US 20170189581A1 · Desai et al. · 2017 [cited by applicant]
US 20170233430A1 · Adams et al. · 2017 [cited by applicant]
US 20170333552A1 · Dubensky, Jr. et al. · 2017 [cited by applicant]
US 20180002369A1 · Biggadike et al. · 2018 [cited by applicant]
US 20180064745A1 · Katibah et al. · 2018 [cited by applicant]
US 20180092937A1 · Oost et al. · 2018 [cited by applicant]
US 20180093964A1 · Altman et al. · 2018 [cited by applicant]
US 20180162899A1 · Bignan et al. · 2018 [cited by applicant]
US 20180186828A1 · Biggadike et al. · 2018 [cited by applicant]
US 20180273578A1 · Oost et al. · 2018 [cited by applicant]
US 20180360979A1 · Mejia Oneto et al. · 2018 [cited by applicant]
US 20190016750A1 · Glick et al. · 2019 [cited by applicant]
US 20190062365A1 · Katibah et al. · 2019 [cited by applicant]
US 20190111163A1 · Mejia Oneto et al. · 2019 [cited by applicant]
US 20190151345A1 · Guiducci et al. · 2019 [cited by applicant]
US 20190160173A1 · Gryaznov et al. · 2019 [cited by applicant]
US 20190183917A1 · Birkus et al. · 2019 [cited by applicant]
US 20190185509A1 · Birkus et al. · 2019 [cited by applicant]
US 20190185510A1 · Birkus et al. · 2019 [cited by applicant]
US 20190185511A1 · Kanne et al. · 2019 [cited by applicant]
US 20190192549A1 · Yoshikawa et al. · 2019 [cited by applicant]
US 20210015932A1 · Mejia Oneto et al. · 2021 [cited by applicant]
US 20210128733A1 · Mejia Oneto et al. · 2021 [cited by applicant]
US 20220105191A1 · Mejia Oneto et al. · 2022 [cited by applicant]
US 20220168426A1 · Mejia Oneto et al. · 2022 [cited by applicant]
US 20220259254A1 · Mejia Oneto et al. · 2022 [cited by applicant]
CN 110496233A · 2019 [cited by applicant]
EP 1867638A1 · 2007 [cited by applicant]
EP 2017281A1 · 2009 [cited by applicant]
EP 2716662A1 · 2014 [cited by applicant]
EP 2719400A2 · 2014 [cited by applicant]
JP 2009513696A · 2009 [cited by applicant]
JP 2010036032A · 2010 [cited by applicant]
WO 2002098883A1 · 2002 [cited by applicant]
WO 2003000708A1 · 2003 [cited by applicant]
WO 2003084571A1 · 2003 [cited by applicant]
WO 2004103272A2 · 2004 [cited by applicant]
WO 2009064738A2 · 2009 [cited by applicant]
WO 2010051530A2 · 2010 [cited by applicant]
WO 2011095336A2 · 2011 [cited by applicant]
WO 2011127149A1 · 2011 [cited by applicant]
WO 2012012612A2 · 2012 [cited by applicant]
WO 2012049624A1 · 2012 [cited by applicant]
WO 2012074840A2 · 2012 [cited by applicant]
WO 2012085789A1 · 2012 [cited by applicant]
WO 2012153254A1 · 2012 [cited by applicant]
WO 2012156918A1 · 2012 [cited by applicant]
WO 2012156919A1 · 2012 [cited by applicant]
WO 2012156920A1 · 2012 [cited by applicant]
WO 2012165462A1 · 2012 [cited by applicant]
WO 2012168512A2 · 2012 [cited by applicant]
WO 2013187954A1 · 2013 [cited by applicant]
WO 2014065860A1 · 2014 [cited by applicant]
WO 2014081299A1 · 2014 [cited by applicant]
WO 2014081300A1 · 2014 [cited by applicant]
WO 2014081301A1 · 2014 [cited by applicant]
WO 2014081303A1 · 2014 [cited by applicant]
WO 2014117001A1 · 2014 [cited by applicant]
WO 2014138186A1 · 2014 [cited by applicant]
WO 2014189806A1 · 2014 [cited by applicant]
WO 2014200767A1 · 2014 [cited by applicant]
WO 2014205126A1 · 2014 [cited by applicant]
WO 2014134689A1 · 2015 [cited by applicant]
WO 2015117235A1 · 2015 [cited by applicant]
WO 2015139025A1 · 2015 [cited by applicant]
WO 2015154082A1 · 2015 [cited by applicant]
WO 2016014799A1 · 2016 [cited by applicant]
WO 2017004192A1 · 2016 [cited by applicant]
WO 2017044983A1 · 2017 [cited by applicant]
WO 2018009648A1 · 2018 [cited by applicant]
WO 2018009652A1 · 2018 [cited by applicant]
WO 2018013887A1 · 2018 [cited by applicant]
WO 2018013908A1 · 2018 [cited by applicant]
WO 2018100558A2 · 2018 [cited by applicant]
WO 2018118665A1 · 2018 [cited by applicant]
WO 2018138684A1 · 2018 [cited by applicant]
WO 2018138685A2 · 2018 [cited by applicant]
WO 2018187740A1 · 2018 [cited by applicant]
WO 2018198076A1 · 2018 [cited by applicant]
WO 2018208667A1 · 2018 [cited by applicant]
WO 2018234805A1 · 2018 [cited by applicant]
WO 2018234807A1 · 2018 [cited by applicant]
WO 2018234808A1 · 2018 [cited by applicant]
WO 2019027858A1 · 2019 [cited by applicant]
WO 2019046511A1 · 2019 [cited by applicant]
WO 2019051488A1 · 2019 [cited by applicant]
WO 2019051489A1 · 2019 [cited by applicant]
WO 2019092660A1 · 2019 [cited by applicant]
WO 2019115402A1 · 2019 [cited by applicant]
WO 2019118839A1 · 2019 [cited by applicant]
WO 2019125974A1 · 2019 [cited by applicant]
WO 2021007160A1 · 2021 [cited by applicant]
Kharkar et al., “Designing degradable hydrogels for orthogonal control of cell microenvironments,” Chem. Soc. Rev., vol. 42, No. 17, pp. 7335-7372 (2013). [cited by applicant]
Kojima et al., “Antitumor activity of timed-release derivative of mitomycin C, agarose bead conjugate,” Chem Pharm Bull, 1978, 26(6): 1818-1824. [cited by applicant]
Koo et al., “Bioorthogonal Copper-Free Click Chemistry In Vivo for Tumor-Targeted Delivery of Nanoparticles,” Angew. Chem. Int. Ed., 2012, vol. 51, pp. 11836-11840. [cited by applicant]
Korpela et al., “A simple method to introduce aldehydic function to agarose,” Anal Biochem, 1976, 71 (1):322-323. [cited by applicant]
Koshy et al., “Click-Crosslinked Injectable Gelatin Hydrogels,” Advanced Healthcare Materials, 2016, DOI: 10.1002/adhm.201500757, 7 pages. [cited by applicant]
Kroemer, G., et al. “Immunogenic cell death in cancer therapy.” Annual review of immunology 31 (2013): 51-72. [cited by applicant]
Landa et al., “Effect of Injectable Alginate Implant on Cardiac Remodeling and Function After Recent and Old Infarcts in Rat,” Circulation, 2008, vol. 117, pp. 1388-1396. [cited by applicant]
Li et al., “Designing hydrogels for controlled drug delivery,” Nature Reviews Materials, 2016, 1(12): 38 pages. [cited by applicant]
Li et al., “Diels-Alder reaction-triggered bioorthogonal protein decaging in living cells,” Natural Chemical Biology, Advanced Online Publication, 2014, vol. 10, 5 pages. [cited by applicant]
Li et al., “Monodispersed PEG-DOTA Conjugated Anti-Tag-72 Diabody Has Low Kidney Uptake and High Tumor to Blood Ratios Resulting in Inproved 64Cu PET Imaging,” J. Nucl. Med., 2010, vol. 51, No. 7, pp. 1139-1146. [cited by applicant]
Li, A., et al. “Activating cGAS-STING pathway for the optimal effect of cancer immunotherapy.” Journal of hematology & oncology 12.1 (2019): 1-12. [cited by applicant]
Lucey, D.R. et al. “Type 1 and type 2 cytokine dysregulation in human infectious, neoplastic, and inflammatory diseases.” Clinical microbiology reviews 9.4 (1996): 532-562. [cited by applicant]
Lueckgen et al., “Hydrolytically-degradable click-crosslinked alginate hydrogels,” Biomaterials, 2018, 181: 189-198. [cited by applicant]
Maggi, A., et al. “Development of a novel antibody-tetrazine conjugate for bioorthogonal pretargeting.” Organic & Biomolecular Chemistry 14.31 (2016): 7544-7551. [cited by applicant]
Matikonda et al., “Bioorthogonal prodrug activation driven by a strain-promoted 1,3-dipolar cycloaddition,” Chem. Sci., 2015, vol. 6, pp. 1212-1218. [cited by applicant]
Medler, T.R. et al. “Immune response to cancer therapy: mounting an effective antitumor response and mechanisms of resistance.” Trends in cancer 1.1 (2015): 66-75. [cited by applicant]
Mejia Oneto et al., “Implantable biomaterial based on click chemistry for targeting small molecules,” Acta Biomaterialia, 2014, vol. 10, pp. 5099-5105. [cited by applicant]
Mejia Oneto et al: In Vivo Bioorthogonal Chemistry Enables Local Hydrogel and Systemic Pro-Drug to Treat Soft Tissue Sarcoma11 , ACS Central Science, vol. 2, No. 7, Jul. 13, 2016 (Jul. 13, 2016), pp. 476-482. [cited by applicant]
Molica Poeta, V. et al. “Chemokines and chemokine receptors: new targets for cancer immunotherapy.” Frontiers in immunology 10 (2019): 379. [cited by applicant]
Nejadmoghaddam, M.-R., et al. “Antibody-drug conjugates: possibilities and challenges.” Avicenna journal of medical biotechnology 11.1 (2019): 3-23. [cited by applicant]
Neves et al., “Imaging Cell Surface Glycosylation in Vivo Using “Double Click” Chemistry,” Bioconjugate Chem., May 5, 2013, vol. 24, pp. 934-941. [cited by applicant]
Niska et al., “Vancomycin-rifampin combination therapy has enhanced efficacy against an experimental [cited by applicant]
Patterson et al., “Finding the Right (Bioorthogonal) Chemistry,” ACS Chem. Biol., 2014, vol. 9, pp. 592-605. [cited by applicant]
Pretze et al., “Recent Trends in Bioorthogonal Click-Radiolabeling Reactions Using Fluorine-18,” Molecules, vol. 18, 2013, pp. 8618-8665; doi:I0.3390/molecules18078618. [cited by applicant]
Ravasi, T., et al. (2007). Systems biology of transcription control in macrophages. Bioessays, 29(12), 1215-1226. [cited by applicant]
Reiner et al., “The inverse electron demand Diels-Alder click reaction in radiochemistry,” J. Labelled Comp. Radiopharm., 2014, vol. 57, No. 4, pp. 285-290. [cited by applicant]
Roach, J. C., et al. “Transcription factor expression in lipopolysaccharide-activated peripheral-blood-derived mononuclear cells.” Proceedings of the National Academy of Sciences 104.41 (2007): 16245-16250. [cited by applicant]
Roers, A. et al. “Recognition of endogenous nucleic acids by the innate immune system.” Immunity 44.4 (2016): 739-754. [cited by applicant]
Rohatagi et al., “Pharmacokinetic and Pharmacodynamic Evaluation of Triamcinolone Acetonide After Intravenous, Oral, and Inhaled Administration,” J. Clin. Pharmacol., 1995, 35: 1187-1193. [cited by applicant]
Rondon, A. et al. “Antibody pretargeting based on bioorthogonal click chemistry for cancer imaging and targeted radionuclide therapy.” Bioconjugate Chemistry 31.2 (2019): 159-173. [cited by applicant]
Rossin et al., “Chemically triggered drug release from an antibody-drug conjugate leads to potent antitumour activity in mice,” Nat Commun, 2018, 9:1484, Supplementary Information Included, 120 pages. [cited by applicant]
Rossin et al., “Highly reactive trans-cyclooctene tags with improved stability for Diels-Alder chemistry in living systems.” Bioconjugate chemistry 24.7 (2013): 1210-1217. [cited by applicant]
Rossin et al., “In vivo chemistry for pretargeted tumor imaging in live mice.” Angewandte Chemie 122.19 (2010): 3447-3450. [cited by applicant]
Rossin et al., “Triggered Drug Release from an Antibody-Drug Conjugate Using Fast “Click-to-Release” Chemistry in Mice,” Bioconjugate Chemistry, 2016, vol. 27, pp. 1697-1706. [cited by applicant]
Rossin et al., Supplementary Information for “Tetrazine-triggered drug release from an antibody-drug conjugate leads to potent antitumour activity in mice,” Nat Commun, 2018, 109 pages. [cited by applicant]
Rossin et al., Supporting Information for “In Vivo Chemistry for Pretargeted Tumor Imagining in Live Mice,” Sections S1-S6, pp. S2-S21 (2010). [cited by applicant]
Royzen et al., “A Photochemical Synthesis of Functionalized trans-Cyclooctenes Driven by Metal Complexation,” J. Am. Chem. Soc., vol. 130, pp. 3760-3761 (2008). [cited by applicant]
Scott, A.M. et al. “Monoclonal antibodies in cancer therapy.” Cancer immunity 12.1 (2012) 1-8. [cited by applicant]
Seif-Naraghi et al., “Safety and Efficacy of an Injectable Extracellular Matrix Hydrogel for Treating Myocardial Infarction,” Science Translation Medicine, 2013, vol. 5, Issue 173, 10 pages. [cited by applicant]
Selvaraj et al., “Tetrazine-tans-cyclooctene ligation for the rapid construction of integrin avβ3 targeted PET tracer based on a cyclic RGD peptide,” Bioorg. Med. Chem. Lett., 2011; 21 (17), pp. 5011-5014; doi:10.1016/j… [cited by applicant]
Selvaraj et al., “trans-Cyclooctene—a stable, voracious dienophile for bioorthogonal labeling”, Current Opinion in Chemical Biology, vol. 17, Issue 5, 2013, pp. 753-760; doi: 10.1016/j.cbpa.2013.07.031. [cited by applicant]
Shelke et al., “Polysaccharide biomaterials for drug delivery and regenerative engineering,” Polym. Adv. Technol., 2014, vol. 25, pp. 448-460. [cited by applicant]
Shuyi, Y., et al. “A critical role of CCR7 in invasiveness and metastasis of SW620 colon cancer cell in vitro and in vivo.” Cancer biology & therapy 7.7 (2008): 1037-1043. [cited by applicant]
Sluyterman et al., “Chromatofocusing: a preparative protein separation method,” TIBS, 1982, pp. 168-170. [cited by applicant]
Strieter, R. M., et al. “The functional role of the ELR motif in CXC chemokine-mediated angiogenesis.” Journal of Biological Chemistry 270.45 (1995): 27348-27357. [cited by applicant]
Tamamis, P. et al. “Elucidating a key component of cancer metastasis: CXCL12 (SDF-1α) binding to CXCR4.” Journal of chemical information and modeling 54.4 (2014): 1174-1188. [cited by applicant]
Tesniere et al., “Immunogenic cancer cell deaths: a key-lock paradigm”, Curr. Op. Immunol, 2008, vol. 20, pp. 504-511. [cited by applicant]
Thalhammer et al., “Reaktivitat Einfacher Offenkettiger Und Cyclischer Dienophile Bei Diels-Alder-Reaktionen Mit Inversem Elektronenbedarf,” Tetrahedron Letters, 1990, vol. 31, No. 47, pp. 6851-6854. [cited by applicant]
ThermoFisher Scientific. Sulfhyryl-reactive Crosslinker Chemistry. Article. Version dated Apr. 1, 2020. Available online at See https://wwhttps://web.archive.org/web/20200401201454/https://www.thermofisher.com/us/en/hom… [cited by applicant]
Thomas et al., “Polyvalent Dendrimer-Methotrexate as a Folate Receptor-Targeted Cancer Therapeutic” Molecular Pharmaceutics, 2012, vol. 9 pp. 2669-2676. [cited by applicant]
Al-Dubai et al., “Biocompatible medical implant materials with binding sites for a biodegradable drug-delivery system,” Nanotechnology, Science and Applications, vol. 2011, No. 4, pp. 87-94 (2011). [cited by applicant]
Alge et al., “Synthetically tractable click hydrogels for three-dimensional cell culture formed using tetrazine-norbornene chemistry,” Biomacromolecules, 2013, 14(4):949-953. [cited by applicant]
Altin et al., “Fabrication of “Clickable” Hydrogels via Dendron-Polymer Conjugates,” Macromolecules, 2010, vol. 43, No. 8, pp. 3801-3808. [cited by applicant]
Antoci et al., “The inhibition of [cited by applicant]
Arenberg, D. A., et al. “Epithelial-neutrophil activating peptide (ENA-78) is an important angiogenic factor in non-small cell lung cancer.” The Journal of clinical investigation 102.3 (1998): 465-472. [cited by applicant]
Arenberg, D. A., et al. “Inhibition of interleukin-8 reduces tumorigenesis of human non-small cell lung cancer in SCID mice.” The Journal of clinical investigation 97.12 (1996): 2792-2802. [cited by applicant]
Barber GN. Sting: infection, inflammation and cancer. Nat Rev Immunol. 2015; 15(12):760-770. [cited by applicant]
Berge et al., “Pharmaceutical Salts,” J. Pharm. Sci., 1977, vol. 66, pp. 1-19. [cited by applicant]
Berger, G. et al. “Pharmacological modulation of the Sting pathway for cancer immunotherapy.” Trends in molecular medicine 25.5 (2019): 412-427. [cited by applicant]
Berraondo, P., et al. “Cytokines in clinical cancer immunotherapy.” British journal of cancer 120.1 (2019): 6-15. [cited by applicant]
Blackman et al., “Tetrazine Ligation: Fast Bioconjugation Based on Inverse-Electron-Demand Diels-Alder Reactivity,” J. Am. Chem. Soc., 2008, vol. 130, pp. 13518-13519. [cited by applicant]
Brinton, L. T., et al. “Metastatic biomarker discovery through proteomics.” Cancer genomics & proteomics 9.6 (2012): 345-355. [cited by applicant]
Brudno et al., “In Vivo Targeting through Click Chemistry,” Chem. Med. Chem., 2015, vol. 10, pp. 617-620. [cited by applicant]
Brudno et al., “On-demand drug delivery from local depots,” J. Control. Release, 2015, http://dx.doi.org/10.1016/j.jconrel.2015.09.011, 10 pages. [cited by applicant]
Brudno et al., “Refilling drug delivery depots through the blood,” PNAS, 2014, 111(35): 12722-12727. [cited by applicant]
Brudno et al., “Replenishable drug depot to combat post-resection cancer recurrence,” Biomaterials, 2018, 178:373-382. [cited by applicant]
Burdick et al., “Acellular Biomaterials: An Evolving Alternative to Cell-Based Therapies,” Science Translation Medicine, Mar. 13, 2013, vol. 5, Issue 176, 4 pages. [cited by applicant]
Carlson et al., “Unraveling Tetrazine-Triggered Bioorthogonal Elimination Enables Chemical Tools for Ultrafast Release and Universal Cleavage,” J. Am. Chem. Soc., 2018, 140(10):3603-3612. [cited by applicant]
Chi, B.-J., et al. “Silencing of CCR7 inhibits the growth, invasion and migration of prostate cancer cells induced by VEGFC.” International journal of clinical and experimental pathology 8.10 (2015): 12533. [cited by applicant]
Chung et al., “Ubiquitous Detection of Gram-Positive Bacteria with Bioorthogonal Magnetofluorescent Nanoparticles,” ACS Nano, 2011, vol. 5, No. 11, pp. 8834-8841, Supporting Documentation Included. [cited by applicant]
Click Chemistry Tools. Sulfhydryl Reactive. Version dated Sep. 27, 2020. Available online at https://web.archive.org/web/20200927065750/https://clickchemistrytools.com/product-category/tco-reagents/sulfhydryl-reactive-t… [cited by applicant]
Cok et al., “Synthesis of Model Network Hydrogels via Tetrazine-Olefin Inverse Electron Demand Diels-Alder Cycloaddition,” Macromol Symp, 2013, 329:108-112. [cited by applicant]
Coviello et al., “Polysaccharide hydrogels for modified release formulations,” Journal of Controlled Release, 2007, vol. 119, pp. 5-24. [cited by applicant]
Czuban, M., et al. “Bio-orthogonal chemistry and reloadable biomaterial enable local activation of antibiotic prodrugs and enhance treatments against [cited by applicant]
De Clercq, E . . . “Mozobil®(Plerixafor, AMD3100), 10 years after its approval by the US Food and Drug Administration.” Antiviral Chemistry and Chemotherapy 27 (2019): 2040206619829382. [cited by applicant]
Deforest et al., “Sequential click reactions for synthesizing and patterning three-dimensional cell microenvironments,” Nature materials: Letters, 2009, vol. 8, pp. 659-664. [cited by applicant]
Desai et al., “Versatile click alginate hydrogels crosslinked via tetrazine-norbornene chemistry,” Biomaterials, 2015, vol. 50, pp. 30-37. [cited by applicant]
Devaraj et al., “Fast and Sensitive Pretargeted Labeling of Cancer Cells through a Tetrazine/trans-Cyclooctene Cycloaddition,” Angew. Chem. Int. Ed., 2009, vol. 48, pp. 7013-7016. [cited by applicant]
Devaraj et al., “Reactive polymer enables efficient in vivo bioorthogonal chemistry,” PNAS, 2012, vol. 109, No. 13, pp. 4762-4767. [cited by applicant]
Dondelinger, M., et al. “Understanding the significance and implications of antibody numbering and antigen-binding surface/residue definition.” Frontiers in immunology 9 (2018): 2278. [cited by applicant]
Dougan, S. K., et al. “Regulation of innate and adaptive antitumor immunity by IAP antagonists.” Immunotherapy 10.9 (2018): 787-796. [cited by applicant]
Eckhouse et al., “Local Hydrogel Release of Recombinant TIMP-3 Attenuates Adverse Left Ventricular Remodeling After Experimental Myocardial Infarction,” Science Translation Medicine, 2014, vol. 6, Issue 223, 10 pages. [cited by applicant]
Eschenhagen et al., “Physiological aspects of cardiac tissue engineering,” Am. J. Physiol. Heart Circ. Physiol., vol. 30, 2012, pp. H133-H143. [cited by applicant]
Fox, E., et al. “Indoximod: an immunometabolic adjuvant that empowers T cell activity in cancer.” Frontiers in oncology 8 (2018): 370. [cited by applicant]
Ganesan, A., et al. “Comprehensive in vitro characterization of PD-L1 small molecule inhibitors.” Scientific reports 9.1 (2019): 12392. [cited by applicant]
Gilchrist, M., et al. “Systems biology approaches identify ATF3 as a negative regulator of Toll-like receptor 4.” Nature 441.7090 (2006): 173-178. [cited by applicant]
Godoy et al., “Enhanced activity of an immobilized lipase promoted by site-directed chemical modification with polymers,” Process Biochemistry, 2010, 45(4):534-541. [cited by applicant]
Guo H. et al: “Functional alginate nanoparticles for efficient intracellular release of doxorubicin and hepatoma carcinoma cell targeting therapy”, International Journal of Pharmaceutics, ELS EV I ER, N L, vol. 451, No.… [cited by applicant]
Haghnegahdar, H., et al. “The tumorigenic and angiogenic effects of MGSA/GRO proteins in melanoma.” Journal of leukocyte biology 67.1 (2000): 53-62. [cited by applicant]
Hashida et al., “Timed-Release of Mitomycin C from Its Agarose Bead Conjugate,” Chem Pharm Bull, 1977, 25:2456-2458. [cited by applicant]
Haun et al., “Bioorthogonal chemistry amplifies nanoparticle binding and enhances the sensitivity of cell detection”, Nature Nanotechnology, 2010, vol. 5, No. 9, pp. 660-665. [cited by applicant]
Hermanto, S., et al. “Molecular dynamic simulation of Trastuzumab F (ab′) 2 structure in corporation with HER2 as a theranostic agent of breast cancer.” Journal of Physics: Conference Series. vol. 835. No. 1. IOP Publis… [cited by applicant]
Hofmann et al., “Targeted delivery of vancomycin to [cited by applicant]
Horita, S., et al. “High-resolution crystal structure of the therapeutic antibody pembrolizumab bound to the human PD-1.” Scientific reports 6.1 (2016): 35297. [cited by applicant]
Hu et al., “Mitochondria-Targeted Cancer Therapy Using a Light-Up Probe with Aggregation-Induced-Emission Characteristics,” Angew. Chem. Int. Ed., 2014, 53:14225-14229. [cited by applicant]
Inoue, K., et al. “Interleukin 8 expression regulates tumorigenicity and metastases in androgen-independent prostate cancer.” Clinical Cancer Research 6.5 (2000): 2104-2119. [cited by applicant]
International Preliminary Report on Patentability for Application No. PCT/US2021/045100 dated Feb. 7, 2023 (12 pages). [cited by applicant]
International Search Report and Written Opinion for Application No. PCT/US2021/045100 dated Nov. 26, 2021 (22 pages). [cited by applicant]
IUPAC 1974 Recommendations for Section E, Fundamental Stereochemistry, in Pure Appl. Chem., 1976, 45: 13-30. [cited by applicant]
Ju, G., et al. “Structure-function analysis of human interleukin-2. Identification of amino acid residues required for biological activity.” Journal of Biological Chemistry 262.12 (1987): 5723-5731. [cited by applicant]
TJWA, “Budesonide inhaled via Turbuhaler: a more effective treatment for asthma than beclomethasone dipropionate via Rotahaler,” Ann. Allergy Asthma Immunol., 1995, 75(2): 107-111. [cited by applicant]
Triton et al., “The anticancer agent adriamycin can be actively cytotoxic without entering cells,” Science, 1982, 217 (4556):248-250. [cited by applicant]
Van De Graaff, M. J., et al. “Conditionally controlling human TLR2 activity via trans-cyclooctene caged ligands.” Bioconjugate chemistry 31.6 (2020): 1685-1692. [cited by applicant]
Van Der Gracht, AMF, et al. “Chemical control over T-cell activation in vivo using deprotection of trans-cyclooctene-modified epitopes.” ACS chemical biology 13.6 (2018): 1569-1576. [cited by applicant]
Verbeke et al., “Multicomponent Injectable Hydrogels for Antigen-Specific Tolerogenic Immune Modulation,” Adv Healthc Mater, 2017, 6 (6), 34 pages. [cited by applicant]
Versteegen et al., “Click to Release: Instantaneous Doxorubicin Elimination upon Tetrazine Ligation,” Angew. Chem. Int. Ed., 2013, vol. 52, pp. 14112-14116. [cited by applicant]
Versteegen et al., “Click-to-Release from trans-Cyclooctenes: Mechanistic Insights and Expansion of Scope from Established Carbamate to Remarkable Ether Cleavage,” Angew. Chem. Int. Ed., 2018, 57:10494-10499. [cited by applicant]
Wang, K., et al. “Post-synthesis DNA modifications using a trans-cyclooctene click handle.” Organic & biomolecular chemistry 13.3 (2015): 909-915. [cited by applicant]
Wu, J. et al. “Immunogenic chemotherapy: dose and schedule dependence and combination with immunotherapy.” Cancer letters 419 (2018): 210-221. [cited by applicant]
Xu, Z., et al. “Novel HER2-targeting antibody-drug conjugates of trastuzumab beyond T-DM1 in breast cancer: trastuzumab deruxtecan (DS-8201a) and (Vic−) trastuzumab duocarmazine (SYD985).” European journal of medicinal … [cited by applicant]
Yoneda, J., et al. “Expression of angiogenesis-related genes and progression of human ovarian carcinomas in nude mice.” JNCI: Journal of the National Cancer Institute 90.6 (1998): 447-454. [cited by applicant]
Zeglis et al., “A Pretargeted PET Imaging Strategy Based on Bioorthogonal Diels-Alder Click Chemistry,” J. Nucl. Med., 2013, vol. 54, No. 8, pp. 1389-1396. [cited by applicant]
Zeglis et al., “Building Blocks for the Construction of Bioorthogonally Reactive Peptides via Solid-Phase Peptide Synthesis,” Chemistry Open Communications, 2014, vol. 3, pp. 48-53, DOI: 10.1002/open.201402000. [cited by applicant]
Zeglis et al., “Modular Strategy for the Construction of Radiometalated Antibodies for Positron Emission Tomography Based on Inverse Electron Demand Diels-Alder Click Chemistry,” Bioconjugate Chemistry, 2011, vol. 22, p… [cited by applicant]
Zhang et al., “An ionically crosslinked hydrogel containing vancomycin coating on a porous scaffold for drug delivery and cell culture,” International Journal of Pharmaceutics, 2008, vol. 353, pp. 74-87. [cited by applicant]
Zhang, H., et al. “Interfacial bioorthogonal cross-linking.” ACS macro letters 3.8 (2014): 727-731. [cited by applicant]
European Patent Office, European Search Report for Application No. 23207387.4, dated Jan. 31, 2024 (7 pages). [cited by applicant]
Srinivasan, S., et al. “SQ3370 Activates Cytotoxic Drug via Click Chemistry at Tumor and Elicits Sustained Responses in Injected and Non-Injected Lesions.” Advanced therapeutics 4.3 (2021): 2000243. [cited by applicant]
Japanese Patent Office. Notification of Reasons for Rejection for Application No. 2023-508513, dated Jun. 25, 2025 (7 pages with translation). [cited by applicant]
U.S. Appl. No. 19/323,247, filed Sep. 9, 2025, by McFarland et al. (pursuant to the waiver of 37 C.F. R. § 1.98(a)(2)(iii) issued by the Office on Oct. 19, 2004). [cited by applicant]